KSQ Therapeutics Inc.’s chief scientific officer, Frank Stegmeier, said that the CRISPRomics technology that drew Takeda Pharmaceutical Co. Ltd. to the table allows, “for the first time, genome-scale functional screening [in vivo as well as in vitro] across multiple disease settings. It really takes the guessing game out of your drug target selection.” Working with “an encyclopedia of gene function,” he said, KSQ aims to identify prospects that can have monotherapy activity in PD-1-refractory solid tumors.